36 results on '"Tang, H"'
Search Results
2. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial
3. 1059P KRAS G12 subtypes with co-mutated TP53, LRP1B, STK11, KEAP1 in lung cancer and their impact on TMB levels, PD-L1 expression and overall survival
4. 425P Novel CoupledCAR technology for treating colorectal cancer
5. 1681P Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection
6. 1063P Comprehensive genomic profiling of leptomeningeal metastases on NSCLC patients through circulating tumor DNA in cerebrospinal fluid
7. 95P Baseline-informed longitudinal monitoring of lung cancer by cell-free DNA methylation profiles
8. 92P Transformative diagnostics in urothelial carcinoma: Utilizing targeted NGS and LP-WGS for non-invasive detection and personalized medicine
9. 91P Ultra-sensitive ctDNA NGS assay enhances genomic profiling for advanced HR-positive, HER2-negative breast cancer on endocrine therapy
10. 1978P Accurate detection of urothelial carcinoma by whole-genome methylation profiling of urinary cell-free DNA
11. 1570P Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
12. 1506P ctDNA testing based on deep NGS predicts treatment efficacy and prognosis in advanced pancreatic cancer patients
13. 1296P A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification
14. 140P Development and validation of nomograms based on clinical characteristics and CT reports for preoperative prediction of precision lymph node dissection in lung cancer
15. 927TiP SKYSCRAPER-09: A phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN)
16. 496P Comprehensive genomic profiling of advanced HR+/HER2- breast cancer patients using liquid biopsy
17. 2402P Urine-based comprehensive genomic profiling reveals mutational landscape in real-world patients with bladder cancer
18. 2401P Detection of molecular recurrence in early-stage bladder cancer patients using a urinary tumor DNA assay after transurethral resection of bladder tumor (TURBT)
19. LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047
20. 1436P Prospective study utilizing ctDNA genome-wide copy number variations for longitudinal monitoring of patients with advanced non-small cell lung cancer
21. 946P Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
22. 642P A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
23. 585P Fragmentomics early detection assay leading to potential clinical benefits in colorectal cancer
24. PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques: A safety study
25. Antidepressants simulate enriched environment enhance platinum chemosensitivity of small cell lung cancer
26. Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142
27. 497O_PR Depression induces poor prognosis via the downregulation of brain derived neurotrophic factor in advanced small cell lung cancer
28. 449PD Relative abundance of EGFR mutations predict tumor metastasis and EGFR-TKIs prognosis in patients with nonsmall cell lung cancer
29. 449PD Relative abundance of EGFR mutations predict tumor metastasis and EGFR-TKIs prognosis in patients with non-small cell lung cancer
30. Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study
31. 1208P - PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques: A safety study
32. 476P - Antidepressants simulate enriched environment enhance platinum chemosensitivity of small cell lung cancer
33. 484PD - Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142
34. 1534P - Antidepressants simulate enriched environment enhance platinum chemosensitivity of small cell lung cancer
35. 479P - Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study
36. 20P Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.